Invitrogen launches microarray system to simplify immunogenetic
15 July 2009
Invitrogen, part of Life Technologies Corporation (NASDAQ:LIFE), has
announced the commercial availability of an automated, research-use
microarray system designed to simplify immunogenetic testing, including
human leukocyte antigen (HLA) research.
The new Prodigy system is an advanced DNA and protein analysis tool
that simplifies and accelerates histocompatibility research, vaccine and
drug development, and disease association studies.
The Prodigy system is the first high-throughput, next-generation,
sequence-specific oligonucleotide probe system that streamlines sample
workflow for hybridizing, detecting and analyzing HLA markers in
large-volume variation analysis and genotyping research studies.
HLA markers are cell-surface proteins that play a key
regulation role in the human immune system, functioning as an alert
mechanism when the body has been invaded by foreign proteins or
molecules, such as bacteria, parasites and viruses.
The Prodigy system represents a significant advancement in
technologies for this type of research, providing scientists with a
simplified workflow for cleaner, consistent and reproducible results,
while reducing hands-on interaction with the system, resulting in
decreased variability, errors and the need for repeat testing.
The Prodigy system features several technological advancements over
other systems in the market. It has 5-times the density capacity of
current bead-based assays and is enabled by push-button, walk-away
automation, enabling researchers to spend valuable time reviewing data
or preparing more samples. Prodigy is inherently scalable to include
multiplexing capability for more than 500 analytes, while providing high
resolution and unmatched efficiency and reliability.
It is also capable of industry-leading throughput that equates to
approximately 290 genotypes in 9 hours, and includes integrated software
that simplifies data analysis and interpretation. And, with capacity for
more than 500 analytes, the Prodigy system is uniquely scalable to
accommodate new alleles to be identified in the future, enabling it to
be easily incorporated into existing infrastructure. This provides
researchers with a future-proof technology that will enable them to not
only expand, but to also advance their research over a significant
period of time.
Jim Janicki, VP & General Manager of Life Technologies’
Transplantation Diagnostics Business said, “The development of the
Prodigy microarray system is the latest development in Invitrogen’s
strategy to make its best-in-class genomic and proteomic technologies
available within the HLA research field. This powerful system provides
an end-to-end solution that will help researchers advance their
Bookmark this page